GeoVax's Gedeptin Shows Disease Stability in Heavily Pretreated Head and Neck Cancer Patients
Key Insights
GeoVax (search) published Phase 1/2 trial results in JCO Oncology Advances showing Gedeptin achieved disease stability in 37.5% of heavily pretreated recurrent head and neck cancer patients.
The gene-directed enzyme prodrug therapy demonstrated an acceptable safety profile with no treatment-related deaths and successful tumor transduction in all evaluable patients.
Study results support advancing Gedeptin into earlier disease settings and combination therapies, particularly with immune checkpoint inhibitors for enhanced therapeutic benefit.
GeoVax (search) Labs announced the publication of Phase 1/2 clinical trial results for Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT), in JCO Oncology Advances, demonstrating favorable safety and evidence of disease stability in patients with recurrent head and neck cancer who had exhausted all standard treatment options.
Trial Design and Patient Population
The multicenter Phase 1/2 trial enrolled patients with recurrent head and neck cancers who had undergone a median of four prior lines of systemic therapy. Patients received therapy on a 28-day schedule, consisting of intratumoral Gedeptin injections followed by intravenous fludarabine. This patient population represented end-stage disease with limited treatment options.
Key Clinical Outcomes
The study demonstrated several important findings in this heavily pretreated population. Three of eight patients (37.5%) achieved stable disease, representing clinical evidence of disease control in patients with end-stage cancer. The therapy showed an acceptable safety profile with no new safety signals, with serious adverse events being uncommon and generally unrelated to treatment. Notably, no deaths were attributed to study therapy.
Tumor biopsies confirmed successful uptake and expression of the therapeutic E. coli PNP (search) transgene in all evaluable patients, supporting the mechanistic foundation of the Gedeptin platform.
Mechanism of Action and Platform Characteristics
Gedeptin is a non-replicating adenoviral vector that delivers the E. coli purine nucleoside phosphorylase (PNP (search)) gene directly into tumor tissue. Following intratumoral injection, patients receive systemic fludarabine, which is converted in PNP-expressing tumor cells into a potent cytotoxic metabolite (2-fluoroadenine, F-Ade).
The platform features a tumor-agnostic mechanism of action driven by localized intratumoral activation of fludarabine into the cytotoxin F-Ade, enabling activity independent of tumor histology or proliferation rate. The therapy also demonstrates a strong bystander effect, where activated F-Ade diffuses to neighboring cancer cells, allowing Gedeptin to kill tumor cells even when only a small fraction is directly transduced.
Future Development Strategy
Study results suggest that earlier intervention, higher vector dosing, improved tumor transduction, or combination therapy may further increase efficacy. Preclinical findings cited in the manuscript show that Gedeptin-mediated tumor destruction may sensitize tumors to checkpoint inhibitors.
"These results support the continued development of Gedeptin in settings where tumor burden is lower, patients are less heavily pretreated, or where combination strategies, particularly with immune checkpoint inhibitors, may amplify therapeutic benefit," stated Kelly T. McKee, MD, MPH, Chief Medical Officer of GeoVax (search). "This aligns with our strategy to advance Gedeptin into neoadjuvant studies for surgically resectable recurrent head and neck cancers."
Combination Therapy Potential
Gedeptin is progressing toward combination-therapy in a neoadjuvant clinical program. Building on robust preclinical data showing that Gedeptin enhances tumor sensitivity to immune checkpoint blockade, GeoVax (search) is advancing plans to evaluate Gedeptin with agents such as pembrolizumab, aiming to strengthen antitumor immune activation.
The therapy's immune-sensitizing properties enhance tumor antigen visibility and may improve responses to immune checkpoint inhibitors, offering a promising therapeutic approach for patients with recurrent head and neck cancers.
J. Marc Pipas, MD, Executive Medical Director, Oncology of GeoVax (search), emphasized the significance of the findings: "Even in a highly refractory patient population with extensive prior treatment, repeated intratumoral dosing of Gedeptin demonstrated a favorable safety profile and evidence of disease stability. Importantly, correlative analyses confirmed robust tumor transduction and PNP (search) expression, a critical mechanistic milestone for gene-directed enzyme prodrug therapy."